Old Web
English
Sign In
Acemap
>
authorDetail
>
Stephen Chuan-Hao Kao
Stephen Chuan-Hao Kao
Pathology
Medicine
Blood–brain barrier
EGFR inhibitors
Cancer
4
Papers
195
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158.
2018
Journal of Clinical Oncology
Hyun Cheol Chung
Jose A. Lopez-Martin
Stephen Chuan-Hao Kao
Wilson H. Miller
Willeke Ros
Bo Gao
Aurélien Marabelle
Maya Gottfried
Alona Zer
Jean-Pierre Delord
Nicolas Penel
Shadia I. Jalal
Lei Xu
Susan Zeigenfuss
Scott K. Pruitt
Sarina Anne Piha-Paul
Show All
Source
Cite
Save
Citations (112)
Phase I study (BLOOM) of AZD3759, a BBB penetrable EGFR inhibitor, in patients with TKI-naïve, EGFRm NSCLC with CNS metastases.
2017
Journal of Clinical Oncology
Myung-Ju Ahn
Dong-Wan Kim
Byoung Chul Cho
Sang-We Kim
Jong Seok Lee
Jin Seok Ahn
Tae Min Kim
Chia-Chi Lin
HyeRyun Kim
Thomas John
Stephen Chuan-Hao Kao
Jonathan W. Goldman
Wu Chou Su
Ronald B. Natale
Philip Overend
Zhenfan Yang
James Chih-Hsin Yang
Show All
Source
Cite
Save
Citations (15)
Phase I study (BLOOM) of AZD3759, a BBB penetrable EGFR inhibitor, in EGFRm NSCLC patients with leptomeningeal metastasis (LM) who progressed after other anti-cancer therapy.
2017
Journal of Clinical Oncology
Byoung Chul Cho
Myung-Ju Ahn
Jong Seok Lee
Dong-Wan Kim
Sang-We Kim
Thomas John
Stephen Chuan-Hao Kao
Jonathan W. Goldman
Wu Chou Su
Ronald B. Natale
Jin Seok Ahn
HyeRyun Kim
Tae Min Kim
Chia-Chi Lin
Philip Overend
Zhenfan Yang
James Chih-Hsin Yang
Show All
Source
Cite
Save
Citations (9)
1